Illumina today announced that it has signed separate agreements with three companies,Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, to expand its reach Non-Invasive Prenatal Testing in Europe. Under the agreement, these companies will uses Illumina’s HiSeq 2500, consumables to perform non-invasive prenatal testing (NIPT).
Biomnis,a leading medical laboratory testing services provided in France will make NIPT available in France. GENOMA Group is a leading molecular genetics laboratory based in Italy and the Center for Human Genetics and Laboratory Diagnostics will offer NIPT in Germany.
Pre-natal testing one of the messiest markets in US, with a lot of lawsuits among the companies offering pre-natal testing. Illumina jumped into the NIPT fray after it acquired Verinata Health, a leading provider of non-invasive pre-natal tests for identifying fetal chromosomal abnormalities in US, for upto $450 million in early 2013.
In the press release announcing the agreement Dr. Charles Woler, CEO of Biomnis Laboratories.said
Biomnis evaluated the different technologies and selected Illumina because of their high level of performance as published in respected, peer-reviewed medical journals, Backed by whole genome sequencing, we look forward to making our highly accurate test accessible to physicians and their patients.”
Dr. Francesco Fiorentino, CEO and Director of Genoma Group Laboratories said
We are excited to offer NIPT through our network with the use of Illumina’s technology. After evaluating different offerings, we selected Illumina’s technology for its deep sequencing capabilities. We are continuously trying to improve our service and offerings for patients and healthcare providers, and we believe our physician customers and the expectant families they work with will be thrilled to have access to this important information in an accurate, safe, and efficient manner.
Dr. Hanns-Georg Klein, CEO of the Center for Human Genetics and Laboratory Diagnostics Martinsried said
We decided on a partnership with Illumina because we share common values regarding delivering high quality products and services. One of the reasons we founded The Prenatalis Consortium was to set standards and to further develop applications of NIPT in close cooperation with leading prenatal centers in Germany. It is crucial to integrate NIPT into the context of established prenatal diagnostics including ultrasound, invasive prenatal diagnostics, and biochemistry.